KR102259588B1 - 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료 - Google Patents

과민성 장 증후군 및 염증성 장 질환의 진단 및 치료 Download PDF

Info

Publication number
KR102259588B1
KR102259588B1 KR1020167011774A KR20167011774A KR102259588B1 KR 102259588 B1 KR102259588 B1 KR 102259588B1 KR 1020167011774 A KR1020167011774 A KR 1020167011774A KR 20167011774 A KR20167011774 A KR 20167011774A KR 102259588 B1 KR102259588 B1 KR 102259588B1
Authority
KR
South Korea
Prior art keywords
antibody
cdt
vinculin
ibs
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167011774A
Other languages
English (en)
Korean (ko)
Other versions
KR20160062161A (ko
Inventor
마크 피멘텔
크리스토퍼 장
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102259588(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Publication of KR20160062161A publication Critical patent/KR20160062161A/ko
Application granted granted Critical
Publication of KR102259588B1 publication Critical patent/KR102259588B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020167011774A 2013-10-09 2014-10-09 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료 Expired - Fee Related KR102259588B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09
US61/888,658 2013-10-09
PCT/US2014/059957 WO2015054529A1 (en) 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Publications (2)

Publication Number Publication Date
KR20160062161A KR20160062161A (ko) 2016-06-01
KR102259588B1 true KR102259588B1 (ko) 2021-06-02

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167011774A Expired - Fee Related KR102259588B1 (ko) 2013-10-09 2014-10-09 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료

Country Status (19)

Country Link
US (2) US9851361B2 (enExample)
EP (1) EP3054977B1 (enExample)
JP (1) JP6567509B2 (enExample)
KR (1) KR102259588B1 (enExample)
CN (1) CN105744956B (enExample)
AU (2) AU2014331841B2 (enExample)
BR (1) BR112016007474A2 (enExample)
CA (1) CA2923651C (enExample)
CL (1) CL2016000820A1 (enExample)
ES (1) ES2892905T3 (enExample)
IL (1) IL244971B2 (enExample)
MX (1) MX383423B (enExample)
NZ (1) NZ717633A (enExample)
PE (1) PE20160882A1 (enExample)
PL (1) PL3054977T3 (enExample)
PT (1) PT3054977T (enExample)
RU (1) RU2683781C2 (enExample)
SG (1) SG11201601733VA (enExample)
WO (1) WO2015054529A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9110081B2 (en) 2009-02-11 2015-08-18 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9702884B2 (en) 2012-09-17 2017-07-11 Cedars-Sinai Medical Center Methods for detecting the presence of irritable bowel syndrome and system for diagnosing same
NZ717633A (en) 2013-10-09 2021-07-30 Cedars Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
CN107003308B (zh) 2014-10-09 2020-02-11 西达-赛奈医疗中心 用于区分肠易激综合征与炎性肠病和乳糜泻的方法和系统
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
KR20230003433A (ko) 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018528A1 (en) 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
US20110305704A1 (en) 2009-02-11 2011-12-15 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of campylobacter jejuni

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
EP2280286A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
CN1914322B (zh) 2003-12-05 2012-05-30 扶桑药品工业株式会社 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
CA2747253A1 (en) 2007-12-20 2009-07-02 Index Diagnostics Ab Method and kit for use in the differentiation of ibd and ibs and further distinction between disease types of ibd
JP5564512B2 (ja) 2008-11-24 2014-07-30 セダーズ−シナイ メディカル センター 抗酸化カンプトセシン誘導体及びその抗酸化、抗新生物ナノスフェア
US20110294726A1 (en) 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
US9702884B2 (en) 2012-09-17 2017-07-11 Cedars-Sinai Medical Center Methods for detecting the presence of irritable bowel syndrome and system for diagnosing same
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
NZ717633A (en) 2013-10-09 2021-07-30 Cedars Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
CN107003308B (zh) 2014-10-09 2020-02-11 西达-赛奈医疗中心 用于区分肠易激综合征与炎性肠病和乳糜泻的方法和系统
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018528A1 (en) 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
US20110305704A1 (en) 2009-02-11 2011-12-15 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of campylobacter jejuni

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Walter Morales et al., 'Antibodies to Cytolethal Distending Toxin B and Auto-Antibodies to Human Vinculin Are Elevated in IBS Subjects', Gastroenterology, 2013, Vol. 144, page S-914. 1부.*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
KR20160062161A (ko) 2016-06-01
PE20160882A1 (es) 2016-09-14
RU2683781C2 (ru) 2019-04-02
BR112016007474A2 (pt) 2017-09-12
CA2923651A1 (en) 2015-04-16
SG11201601733VA (en) 2016-04-28
JP6567509B2 (ja) 2019-08-28
PT3054977T (pt) 2021-10-14
AU2014331841A1 (en) 2016-03-24
US20180196063A1 (en) 2018-07-12
WO2015054529A1 (en) 2015-04-16
IL244971A0 (en) 2016-05-31
CN105744956A (zh) 2016-07-06
IL244971B1 (en) 2023-08-01
JP2017502253A (ja) 2017-01-19
CL2016000820A1 (es) 2016-09-23
US20170038393A1 (en) 2017-02-09
CN105744956B (zh) 2021-07-20
IL244971B2 (en) 2023-12-01
EP3054977A4 (en) 2017-04-12
CA2923651C (en) 2023-03-14
US9851361B2 (en) 2017-12-26
HK1221898A1 (zh) 2017-06-16
AU2020203468A1 (en) 2020-06-18
ES2892905T3 (es) 2022-02-07
PL3054977T3 (pl) 2021-12-20
MX383423B (es) 2025-03-14
AU2014331841B2 (en) 2020-03-12
EP3054977B1 (en) 2021-07-21
NZ717633A (en) 2021-07-30
EP3054977A1 (en) 2016-08-17
US10352944B2 (en) 2019-07-16
MX2016004167A (es) 2016-06-24
RU2016116766A (ru) 2017-11-15

Similar Documents

Publication Publication Date Title
US10352944B2 (en) Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10690679B2 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10466254B2 (en) Method of measuring a level of anti-vinculin antibodies in a biological sample
KR20190111094A (ko) 경피증의 진단
US20240159772A1 (en) Methods for Detecting and Treating Irritable Bowel Syndrome
HK1221898B (en) Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
HK1234824A1 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
HK1234824B (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250528

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250528

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250528